Avapritinib combo for relapsed AML after transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (avapritinib, azacitidine, and venetoclax) for people whose acute myeloid leukemia (AML) has returned after a stem cell transplant. It targets a specific genetic change (C-KIT mutation) to try to stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your leukemia has come back after a stem cell transplant (bone marrow transplant).
- Your leukemia cells have a specific change in the C-KIT gene (D816 or N822).
- You have a certain fusion gene (CBFB::MYH11 or RUNX1::RUNX1T1).
- You are in fairly good health (able to do daily activities, with good heart, liver, and kidney function).
- You do not have uncontrolled active GVHD (graft-versus-host disease) or central nervous system leukemia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
This trial tests a new drug called AK117 combined with two standard AML medicines (azacitidine and venetoclax) for people with acute myeloid leukemia who haven't had certain prior treatments. The goal is to see if this combination works better and is safe.
This trial tests a targeted drug called avapritinib in children and teens with a specific type of leukemia (CBF-AML) that has a KIT gene change and has come back or not responded to treatment. The goal is to see if avapritinib is safe and effective for these patients.
This trial tests whether taking avapritinib (a targeted pill) after a stem cell transplant can help keep leukemia in remission for people whose AML has a KIT mutation. It's a maintenance therapy meant to prevent relapse.
This trial tests a new targeted therapy for a specific type of leukemia (CBF-AML with a KIT gene change) in people who have not yet had treatment. The goal is to see if adding a KIT inhibitor to standard chemotherapy can improve outcomes.
Hear when a new AML (Acute Myelogenous Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.